PF-08046054 by Pfizer for Ovarian Cancer: Likelihood of Approval

PF-08046054 is under clinical development by Pfizer and currently in Phase I for Ovarian Cancer.

Rona Therapeutics raises $35M; Actuate now plans for $22M IPO

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 20, 2024

Does being obese or overweight reduce semen quality?

Researchers in China found significant associations between obesity and reduced semen quality in men, with the greatest declines in those with severe obesity. The study

July 16, 2024

Groundbreaking model predicts heart attack risk months in advance

Study introduces a novel biomarker-based model to predict imminent myocardial infarction (IMI), identifying key proteins and metabolites that could revolutionize early detection and prevention strategies.

February 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.